The Transcatheter Cardiovascular Therapeutics (TCT) conference announced its lineup for late-breaking clinical trials and first report investigations that will be a presented Sept. 13-15 at the scientific sessions in Washington, D.C.

Lowering the amount of contrast used and encouraging more oral hydration before and after a PCI procedure reduced contrast-induced acute kidney injury by 21 percent, according to a study published online July 29 in Circulation: Cardiovascular Quality and Outcomes. 

Initiatives to provide timely treatment for patients with acute MI overall appear to making an impact but hospitals still have room to improve in their care of patients who present off-hours, an analysis published online July 29 in Circulation: Cardiovascular Quality and Outcomes suggests.

Boston Scientific Corporation has initiated full commercial launch of the new POLARIS Imaging System.  This system will support the Boston Scientific family of intravascular ultrasound (IVUS) catheters, including coronary, peripheral and intra-cardiac echo products.  The POLARIS System offers enhanced ease-of-use and more powerful processing capabilities.  Its modular design would also support the planned release of new Boston Scientific imaging products including a fractional flow reserve (FFR) wire, a new family of IVUS catheters, enhanced software features and better system control tools.

Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation  has received CE Mark and begun the European market launch of the Agent Paclitaxel-Coated PTCA Balloon Catheter.  The Agent Drug-Coated Balloon (DCB) provides physicians with an additional alternative to treat both in-stent restenosis (ISR) and de novo small vessel coronary disease.

Physicians in the U.S. who treat patients with multivessel coronary disease rarely turn to a hybrid approach for therapy. Over a two-year period, only 0.48 percent of CABG procedures included hybrid coronary revascularization (HCR), reported a study published online July 23 in Circulation.

The FDA approved Boston Scientific’s Rebel stent system for treating patients with coronary artery disease. The bare-metal stent consists of a platinum chromium alloy and uses the same design as the company’s Promus Premier stent.

Due to rapidly increasing demand for its cardiac cath lab PCI, Diagnostic and Carotid Stenting accreditation and quality review services, ACE is proud to lead the way in offering four new accreditation and external review services for catheter based cardiovascular procedures to include: Congenital Heart Disease, Electrophysiology including Implants & Devices, Transcatheter Valve Therapies and Peripheral Vascular Procedures.